Vericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22.5%, EPS grew 500.0% and free cash flow grew 17,503.7%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow VCEL
Vericel Corporation (VCEL) EV/Sales
As of 16 October 2026, Vericel Corporation (VCEL) trades at a EV/Sales of 6.2×. Over the past ten years it has ranged from 0.1× (January 2015) to 23.1× (June 2021); the current reading is higher than 43% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.1× | (43.51%) |
| FY2024 | 10.8× | 38.21% |
| FY2023 | 7.8× | 19.19% |
| FY2022 | 6.6× | (40.91%) |
| FY2021 | 11.1× | 3.42% |
| FY2020 | 10.8× | 77.26% |
| FY2019 | 6.1× | (12.98%) |
| FY2018 | 7.0× | 138.53% |
| FY2017 | 2.9× | 194.39% |
| FY2016 | 1.0× | 8.65% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.9× | 34.75% |
| Mar 2026 | 5.2× | (15.88%) |
| Dec 2025 | 6.1× | 7.77% |
| Sep 2025 | 5.7× | (30.70%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IRON Disc Medicine, Inc. compare | n/m |
| PHVS Pharvaris N.V. compare | n/m |
| VERA Vera Therapeutics, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | 1.1× |
| NVAX Novavax, Inc. compare | 3.4× |
| AUPH Aurinia Pharmaceuticals Inc compare | 5.6× |
| VCEL Vericel Corporation | 6.2× |
| VRDN Viridian Therapeutics, Inc. compare | 18.6× |
| IMNM Immunome, Inc. compare | 107× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)